EVERSANA Unveils EVERSANA ORCHESTRATE PV, An AI-Propelled Solution to Shape the Future of Pharmacovigilance

Expert-led AI multi-platform solution to streamline drug safety workflows with unmatched speed, accuracy and quality

CHICAGO, July 17, 2025 /PRNewswire/ -- EVERSANA, a leading provider of global commercial services to the life sciences industry, today announced a new milestone to transform pharmaceutical operations with the launch of EVERSANA ORCHESTRATE PV. The unified, AI-propelled solution accelerates critical pharmacovigilance workflows, including literature monitoring and aggregate authoring and reporting - driving unmatched speed, accuracy and quality across the drug safety sector. EVERSANA ORCHESTRATE PV automates and customizes workflows for scalability and has been proven to accelerate the operations lifecycle by as much as 50 percent while reducing manual labor investment by up to 40 percent.

"We remain as committed as ever to 'pharmatize AI.' Today we bring pharmacovigilance leaders the long-overdue intelligent, scalable solution to complex and costly PV workflows," said Jim Lang, CEO, EVERSANA. "Through the power of our ORCHESTRATE operating system, our best-in-class experts in drug safety, and rapidly evolving AI-solutions, we're streamlining safety processes, ensuring global compliance, and helping influence better patient outcomes."

EVERSANA ORCHESTRATE PV's global, multi-language literature monitoring platform, developed in partnership with AI-first digital engineering company Quantiphi, accelerates monitoring five times faster than industry standards. With 99.8 percent accuracy, the platform seamlessly integrates into Oracle Argus Cloud, PubMed, Embase and other known drug safety literature platforms, creating unification across all processes.

EVERSANA ORCHESTRATE PV's aggregate authoring and reporting platform generates common reports needed for regulatory requirements such as the Periodic Adverse Drug Experience Report (PADER.) The tool automates reporting and SLA notifications, saving on average 30 minutes per report from the previous manual process, and through the power of AI, reduces human error by 90% and ensures overall 99% accuracy, driving actionable insights.

EVERSANA has a long-standing reputation for award-winning compliance innovations and partnerships. "Together with EVERSANA, we are applying the full potential of AI and Generative AI to some of the most critical challenges in life sciences," Quantiphi Co-founder, Asif Hasan said. "We're reimagining pharmacovigilance processes and operations, helping clients accelerate innovation, reduce risk and drive sustainable value at scale through GenAI."

In June 2024, EVERSANA also announced an agreement with Oracle. Most recently in April 2025, EVERSANA launched EVERSANA ORCHESTRATE MLR, a first-of-its-kind solution to bring unmatched efficiency and innovation to the medical, legal and regulatory review process.

To learn more about EVERSANA ORCHESTRATE PV and schedule a demo, visit EVERSANA.ai/ORCHESTRATEPV.

About EVERSANA®
EVERSANA® is a leading independent provider of global services to the life sciences industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and X. 

About Quantiphi
Quantiphi is an award-winning AI-first digital engineering company driven by the desire to reimagine and realize transformational opportunities at the heart of business. Since its inception in 2013, Quantiphi has solved the toughest and most complex business problems by combining deep industry experience, disciplined cloud and data engineering practices, and cutting-edge artificial intelligence research to achieve accelerated and quantifiable business results. Learn more at Quantiphi.com and follow us on LinkedIn, X, formerly Twitter, Instagram and YouTube. 

MEDIA CONTACTS

EVERSANA
Matt Braun
Vice President, Corporate Communications
[email protected]

SOURCE EVERSANA